Verily’s quest to become a major player in the life sciences has resulted in a scattershot string of efforts, but as the company plans for 2022, charging forward with its clinical trial strategy will be the Alphabet spinout’s priority.
Speaking at the 2021 STAT Summit, Amy Abernethy, president of Verily’s clinical trials platform, said that company is gearing up to release a new “blueprint” for its future in the space, and spelled out some of the pillars of the approach. The company’s strategy includes making it easier for a diverse pool of people to participate in trials, enabling more robust data collection, and preparing for more complex study designs that the first two pillars enable.
“Practically speaking, we are going to focus on building longitudinal datasets that can be put to use for understanding the contours of illness that can be put to use to test multiple different treatments simultaneously,” said Abernethy, adding that it’s important to be able to reach participants wherever they are to collect patient-reported measures. She added that the company hopes to create a vast repository combining real-world data, medical records, and traditional clinical trial data.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
